<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;CTNNA1&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>CTNNA1</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>CTNNA1</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela Hebbard, MD, FRCS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kasmintan A Schrader, MBBS, FRCPC, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3550485701"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing of the<em> CTNNA1 </em>gene. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the tested individual. These subjects are discussed separately [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3974459099"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H3458207427"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>).</p><p>Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the genotype</strong> – Identifies variants. Should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or comparable accreditation body in other jurisdictions, if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding, negative finding in an individual with a suspected hereditary diffuse gastric cancer [HDGC] syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified. May require updating, especially for variants of uncertain significance (VUS). </p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H640391808"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>The <em>CTNNA1 </em>gene encodes alpha-1 catenin which plays an important role in the cell adhesion process by connecting cadherin proteins which are located on the cell surface and promote cell-cell adhesion. Pathogenic variants in <em>CTNNA1</em> can lead to HDGC syndrome, an autosomal dominant disorder. However, most cases of HDGC are due to pathogenic variants in the tumor suppressor gene,<em> CDH1</em>, encoding cadherin 1, the epithelial cell-cell adhesion protein.</p><p class="headingAnchor" id="H3788834619"><span class="h3">Gastric cancer</span><span class="headingEndMark"> — </span>HDGC is an inherited form of diffuse-type gastric cancer, a highly invasive tumor. Penetrance for diffuse-type gastric cancer in individuals with a pathogenic <em>CTNNA1 </em>variant and the age of onset are uncertain. However, intramucosal foci of diffuse gastric cancer have been found in prophylactic gastrectomy specimens from affected individuals [<a href="#rid2">2-4</a>], suggesting that these individuals are at risk for HDGC and warrant at least endoscopic surveillance or definitive prophylactic gastrectomy. Analysis<em> </em>of<em> CTNNA1</em> variants from commercial multigene panel testing suggests that the penetrance for gastric cancer may be lower than expected, although specific variants may have a significant risk for early onset diffuse gastric cancer [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Carriers of CTNNA1 pathogenic or likely pathogenic variants'</a>.) </p><p class="headingAnchor" id="H2757928276"><span class="h3">Breast cancer</span><span class="headingEndMark"> — </span>Unlike individuals with HDGC syndrome due to a pathogenic variant in <em>CDH1</em> who are at an increased risk for invasive lobular breast cancer (ILBC), the risk of ILBC in individuals with pathogenic variants in <em>CTNNA1</em> has not definitively been established. </p><p class="headingAnchor" id="H1346520305"><span class="h1">IMPLICATIONS OF A PATHOGENIC OR LIKELY PATHOGENIC VARIANT</span><span class="headingEndMark"> — </span>We consider all individuals with a pathogenic or likely pathogenic variant in <em>CTNNA1 </em>to be at risk for hereditary diffuse gastric cancer (HDGC) syndrome, regardless of the initial reason for testing. Discussion should include the range of associated risks, possible interventions for cancer surveillance or risk reduction, and implications for family members. (See <a class="local">'At-risk relatives'</a> below.)</p><p>We adhere to guidelines by the International Gastric Cancer Linkage Consortium (IGCLC) for cancer surveillance and risk reduction [<a href="#rid5">5</a>]. Findings in family members (type of cancers, age of onset) may also inform surveillance.</p><p>Evaluations and interventions to reduce the risk of cancers associated with HDGC syndrome include  (<a class="graphic graphic_algorithm graphicRef131798" href="/z/d/graphic/131798.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric cancer</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual screening with an upper endoscopy with biopsies (Cambridge protocol) to screen for gastric cancer. Endoscopy should be performed in a center of expertise. Individuals who carry a pathologic <em>CTNNA1</em> mutation should be screened for infection with <em>Helicobacter pylori </em>(<em>H. pylori</em>) and treated if positive. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Diagnostic tests'</a> and  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults", section on 'Initial antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We individualize decision-making about prophylactic gastrectomy in the context of the penetrance of HDGC in the family. At the very least, asymptomatic carriers of pathogenic or likely pathogenic <em>CTNNA1</em> variants should undergo counseling, risk assessment, and yearly surveillance endoscopy in an expert center. (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Carriers of CTNNA1 pathogenic or likely pathogenic variants'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who chose to undergo surveillance upper endoscopy to screen for gastric cancer should be informed that there is no reliable endoscopic screening test for the early diagnosis of diffuse gastric cancer. Gastric cancers that arise in patients with HDGC are signet ring cancers that are located beneath an intact surface epithelium and only become visible on direct mucosal evaluation later in the disease process. (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Carriers of CTNNA1 pathogenic or likely pathogenic variants'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with signet ring cells or diffuse gastric cancer on gastric biopsy should undergo total gastrectomy. (See  <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">"Surgical management of invasive gastric cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> –<strong> </strong>The risk of invasive lobular breast cancer in individuals with pathogenic variants in <em>CTNNA1</em> is unclear. A comprehensive breast cancer risk assessment should be performed. Depending on personal and family history of cancer, referral to a high-risk breast cancer clinic may be appropriate with intensification of surveillance and individualized decision-making on the benefits of risk-reducing mastectomy or chemoprevention. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'CDH1 (Hereditary diffuse gastric cancer syndrome)'</a> and <a class="local">'Breast cancer'</a> above and  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Carriers of CTNNA1 pathogenic or likely pathogenic variants'</a> and  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a>.)</p><p></p><p class="headingAnchor" id="H847216049"><span class="h1">IMPLICATIONS OF A NEGATIVE TEST</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic variants were identified  (<a class="graphic graphic_algorithm graphicRef131798" href="/z/d/graphic/131798.html" rel="external">algorithm 1</a>). However, some tests only evaluate a subset of variants; pathogenic variants might be present in other parts of the gene (if testing was not comprehensive) or in other genes (eg, <em>CDH1</em>).</p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>CTNNA1</em> variant is known and the tested individual does not have that variant, usually they can be reassured that they are not at increased risk for hereditary diffuse gastric cancer (HDGC) syndrome, with caveats outlined above (see <a class="local">'How to read the report'</a> above). However, it is important to provide an individualized risk assessment based on family history and other risk factors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>CTNNA1 </em>variant is not known and results of genetic testing are negative, the extent of additional testing depends on the personal and family history. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to guide additional genetic testing based on the personal and family history. Intensive endoscopic screening may be considered in patients who meet HDGC criteria. (See <a class="local">'Locating an expert'</a> below.)</p><p></p><p class="headingAnchor" id="H2078017067"><span class="h1">IMPLICATIONS OF A VUS</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history. Annual endoscopic surveillance for gastric cancer is suggested in patients with a <em>CTNNA1</em> VUS for at least two years, ideally as part of a research study [<a href="#rid5">5</a>]. Women with a <em>CTNNA1 </em>VUS should receive individualized breast cancer risk assessment and surveillance recommendations  (<a class="graphic graphic_algorithm graphicRef131798" href="/z/d/graphic/131798.html" rel="external">algorithm 1</a>).</p><p>New information on VUSs may become available; the testing laboratory or other resources should be consulted periodically for updates (eg, annually). (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Surveillance for breast cancer'</a>.)</p><p>The implications of genetic test results should be discussed with the individual's oncologist or surgeon; in some cases, referral to a specialist in hereditary cancer syndromes may be appropriate. </p><p class="headingAnchor" id="H424624707"><span class="h1">CONSIDERATIONS FOR FAMILY MEMBERS</span></p><p class="headingAnchor" id="H2106682898"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Reproductive counseling is appropriate for individuals with a pathogenic or likely pathogenic <em>CTNNA1 </em>variant who are considering childbearing.</p><p>Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.) </p><p class="headingAnchor" id="H610326293"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals with a pathogenic variant or likely pathogenic variant in <em>CTNNA1 </em>should inform their at-risk relatives about the importance of genetic counseling and possible testing. </p><p class="bulletIndent1"><span class="glyph">●</span>If the disease-causing variant in the family is not a de novo variant, the risk of having inherited the variant is 50 percent for first-degree relatives, including siblings and parents; if one parent carries the variant, then the risk to siblings is also 50 percent. Others at risk may include aunts, uncles, nieces, nephews, and cousins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually, the disease-causing variant is inherited from the side of the family with a history of gastric cancer. If possible, it is recommended to test a parent or other relative with cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Generally, predictive genetic testing is undertaken in adulthood; however, genetic testing may be appropriate to consider as early as mid- to late adolescence depending on an earlier age of onset for diffuse gastric cancer in the family. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a> and <a class="local">'Implications of a pathogenic or likely pathogenic variant'</a> above.)</p><p></p><p class="headingAnchor" id="H1730114991"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H94599367"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary diffuse gastric cancer (HDGC) syndrome – (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer"</a> and  <a class="medical medical_review" href="/z/d/html/8041.html" rel="external">"Surgical management of hereditary diffuse gastric cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variant classification – (See  <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Clinical classification of pathogenicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling – (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="headingAnchor" id="H649103819"><span class="h2">Locating an expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=133261" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=133261" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=133261" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Majewski IJ, Kluijt I, Cats A, et al. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013; 229:621.</a></li><li><a class="nounderline abstract_t">Benusiglio PR, Colas C, Guillerm E, et al. Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. Gastric Cancer 2019; 22:899.</a></li><li><a class="nounderline abstract_t">Clark DF, Michalski ST, Tondon R, et al. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet Med 2020; 22:840.</a></li><li><a class="nounderline abstract_t">Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020; 21:e386.</a></li></ol></div><div id="topicVersionRevision">Topic 133261 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23208944" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anα-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30515673" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical implications of CTNNA1 germline mutations in asymptomatic carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32051609" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758476" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hereditary diffuse gastric cancer: updated clinical practice guidelines.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
